Naurex raises $18M for Ph2 depression program

Evanston, IL-based Naurex is banking an $18 million Series A for its work on a new treatment for depression. And it's gained some significant support from a group of venture backers which includes a trio of pharma investment arms. Adams Street Partners and Latterell Venture Partners led the round with  Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire taking part. Much of the money will be used for a Phase II trial of GLYX-13, a glycine-site functional partial agonist selective modulator of the NMDA receptor. Naurex release

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.